Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC

Metastatic Breast Cancer (MBC) Clinical Trial

Official title:
A Randomized Phase III Trial of Gemcitabine and Docetaxel Versus Gemcitabine and Paclitaxel in Patients With Metastatic Breast Cancer: A Comparison of Different Schedules

Status Completed

Clinical Trial Summary

Multi-center, randomized Phase III study. 4 arms. 360 Patient to enroll. Purpose is evaluate time to progression disease (PD).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Metastatic Breast Cancer (MBC)

Clinical Trial Details

NCT number	NCT00236899
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	September 2005
Completion date	August 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06143553` - Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).	Phase 3
Active, not recruiting	`NCT02605486` - Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)	Phase 1/Phase 2
Terminated	`NCT01495247` - Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT01471847` - A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab	Phase 1
Completed	`NCT02312622` - Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer	Phase 2